All In Biotech

Drug Trial Radar · NCT06068946

VK2735 for Weight Management Phase 2

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of VK2735 for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition

Last checked: Nov 19, 2026Latest source record: Feb 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 176 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

176

Actual

Start

Aug 31, 2023

Primary completion

Feb 27, 2024

Study completion Apr 2, 2024

Sponsor

Lead sponsor
Viking Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Oct 5, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. VK2735 or matched placebo will be administered once weekly.

Conditions

  • Weight Loss

Interventions

  • VK2735Biological

    VK2735 is a peptide GLP-1 and GIP dual agonist

  • PlaceboBiological

    Placebo comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent (relative) change from baseline to Week 13 in body weightTime frame: 13 weeks

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Viking Clinical Site #119

    Birmingham, Alabama

  • Viking Clinical Site #114

    Long Beach, California

  • Viking Clinical Site #110

    Los Angeles, California

  • Viking Clinical Site #113

    Tustin, California

  • Viking Clinical Site #116

    Clearwater, Florida

  • Viking Clinical Site #106

    Clearwater, Florida

  • Viking Clinical Site #112

    Jacksonville, Florida

  • Viking Clinical Site #105

    Ocoee, Florida

  • Viking Clinical Site #107

    Port Orange, Florida

  • Viking Clinical Site #104

    Indianapolis, Indiana

  • Viking Clinical Site #103

    Louisville, Kentucky

  • Viking Clinical Site #109

    Marrero, Louisiana

  • Viking Clinical Site #102

    Kansas City, Missouri

  • Viking Clinical Site #111

    Butte, Montana

  • Viking Clinical Site #108

    Knoxville, Tennessee

  • Viking Clinical Site #101

    Austin, Texas

  • Viking Clinical Site #118

    Austin, Texas

  • Viking Clinical Site #100

    Phoenix, Texas

  • Viking Clinical Site #115

    San Antonio, Texas

  • Viking Clinical Site #117

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.